Humacyte Inc
NASDAQ:HUMA

Watchlist Manager
Humacyte Inc Logo
Humacyte Inc
NASDAQ:HUMA
Watchlist
Price: 1.0158 USD -0.41% Market Closed
Market Cap: $190.2m

Gross Margin

60.5%
Current
Declining
by 2.2%
vs 3-y average of 62.7%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
60.5%
=
Gross Profit
$951k
/
Revenue
$1.6m

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
60.5%
=
Gross Profit
$951k
/
Revenue
$1.6m

Peer Comparison

Country Company Market Cap Gross
Margin
US
Humacyte Inc
NASDAQ:HUMA
187.3m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
394.7B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.9B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.2B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.6B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.4B AUD
Loading...
NL
argenx SE
XBRU:ARGX
44.1B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.5B USD
Loading...

Market Distribution

Higher than 70% of companies in the United States of America
Percentile
70th
Based on 12 729 companies
70th percentile
60.5%
Low
-24 813% — 28.9%
Typical Range
28.9% — 60.5%
High
60.5% — 10 905 714.3%
Distribution Statistics
the United States of America
Min -24 813%
30th Percentile 28.9%
Median 43%
70th Percentile 60.5%
Max 10 905 714.3%

Humacyte Inc
Glance View

Market Cap
190.2m USD
Industry
Biotechnology

Humacyte, Inc. engages in the manufacture of human acellular matrix products for vascular and non-vascular applications. The company is headquartered in Durham, North Carolina and currently employs 145 full-time employees. The company went IPO on 2020-09-22. The company is developing a portfolio of human acellular vessels (HAVs) with varying diameters and lengths. The HAV cabinet would initially target the vascular repair, reconstruction and replacement market, including vascular trauma; atrioventricular (AV) access for hemodialysis; peripheral arterial disease (PAD); and coronary artery bypass grafting (CABG). The firm has developed a paradigm for manufacturing human tissues that is intended to mimic key aspects of human physiology. The company is developing and manufacturing acellular tissues to address life- and limb-threatening vascular conditions while focusing on potential future applications for complex tissue and organ diseases. The company is also engaged in developing its HAVs for pediatric heart surgery and the delivery of cellular therapies, including pancreatic islet cell transplantation to treat Type 1 diabetes.

HUMA Intrinsic Value
Not Available
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
60.5%
=
Gross Profit
$951k
/
Revenue
$1.6m
What is Humacyte Inc's current Gross Margin?

The current Gross Margin for Humacyte Inc is 60.5%, which is below its 3-year median of 62.7%.

How has Gross Margin changed over time?

Over the last 6 months, Humacyte Inc’s Gross Margin has decreased from 71.6% to 60.5%. During this period, it reached a low of 56% on Jun 30, 2025 and a high of 71.6% on Mar 31, 2025.

Back to Top